Evaluation of an automated closed fluid management device for processing expanded cytokine‐induced killer cells to use in immunotherapy programs for cancer

Giancola, Raffaella; Olioso, P; Riti, Maria Di; Capone, Anita; Contento, Alessandro; Pompetti, Franca; Iacone, A

doi:10.1111/j.1537-2995.2007.01587.x

Cited by 7 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-2 and fresh medium were added every 3 to 4 days without opening the system. In fact, cell washing procedures and addition of media were performed with CytoMate 1 (Baxter Oncology, Chicago, USA, currently distributed in Italy by Milteny Biotec, Bologna, Italy) an automated, closed fluid management system [17].…”

Section: Generation Of Cik Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial

Olioso

Giancola

Riti

et al. 2009

Hematological Oncology

Self Cite

130

View full text Add to dashboard Cite

show abstract

Section: Generation Of Cik Cellsmentioning

confidence: 99%

“…Patients who experienced a CR or a SD had a significantly longer OS compared with non-responders. The median OS is 36 or 18 months, respectively, while four non-responding patients died for PD with a median survival of 6 months (range, [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19].…”

Section: Tumour Responses and Overall Survivalmentioning

confidence: 99%

Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial

Olioso

Giancola

Riti

et al. 2009

Hematological Oncology

Self Cite

130

View full text Add to dashboard Cite

show abstract

“…This unique flow pattern creates flow at the membrane, constantly sweeping the surface to prevent the cellular components from depositing on and clogging or fouling the membrane, while continually replenishing the medium to be filtered 70. CytoMate (Baxter International Inc.) is an automatic cell washing device that utilizes a spinning membrane to ensure cell filtration against a counter-flow buffer circulation 71. The closed system has automatic user-definable programming that allows for efficient separation with low risk of contamination 72.…”

Section: Centrifugation-free Technologiesmentioning

confidence: 99%

Traditional and emerging technologies for washing and volume reducing blood products

Lu¹,

Lezzar²,

Vörös³

et al. 2019

JBM

View full text Add to dashboard Cite

Millions of blood components including red blood cells, platelets, and granulocytes are transfused each year in the United States. The transfusion of these blood products may be associated with adverse clinical outcomes in some patients due to residual proteins and other contaminants that accumulate in blood units during processing and storage. Blood products are, therefore, often washed in normal saline or other media to remove the contaminants and improve the quality of blood cells before transfusion. While there are numerous methods for washing and volume reducing blood components, a vast majority utilize centrifugation-based processing, such as manual centrifugation, open and closed cell processing systems, and cell salvage/autotransfusion devices. Although these technologies are widely employed with a relatively low risk to the average patient, there is evidence that centrifugation-based processing may be inadequate when transfusing to immunocompromised patients, neonatal and infant patients, or patients susceptible to transfusion-related allergic reactions. Cell separation and volume reduction techniques that employ centrifugation have been shown to damage blood cells, contributing to these adverse outcomes. The limitations and disadvantages of centrifugation-based processing have spurred the development of novel centrifugation-free methods for washing and volume reducing blood components, thereby causing significantly less damage to the cells. Some of these emerging technologies are already transforming niche applications, poised to enter mainstream blood cell processing in the not too distant future.

show abstract

“…Several technologies are available for the downstream processing steps of cell therapy products and most of them are still being evaluated for commercialization purpose [27]. In fact, Automated washing machine (cytomate) has shown 95% post washing viability of cells, but low cell recovery of 85.3% [28,29]. In centrifugation based Cell processor (COBE 2991) shown a viable cell recovery of 73% compared to cytomate of 95% [30][31][32].…”

Section: Post-trypsinization Processmentioning

confidence: 99%

Cell Therapy Manufacturing and Quality Control: Current Process and Regulatory Challenges

Kolkundkar¹

2014

J Stem Cell Res Ther

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSC) are multipotent stem cells that have been isolated from multiple tissue sources and are currently being used to demonstrate their therapeutic efficacy against various clinical indications. Dramatic increase in the use of MSCs for tissue engineering applications and in regenerative medicine in past two decades raises an increasing demand for cGMP (current Good Manufacturing Practice) based large-scale manufacturing process of MSCs and characterization of these cells. The challenge is to assure the safety and high-quality of cells that will ultimately be therapeutically effective. GMP compliance processing such as cell culture, expansion and cryopreservation is mandatory for making the cell therapy effective. MSCs from various tissue sources should be cultured for scale-up according to regulatory compliance to optimize culture conditions and to ensure the safety of these manufactured cell populations. This review describes cGMP compliances and manufacturing process of bone marrow derived MSCs; specifically in the context of establishing the process flow and in-process controls for the manufacturing process. Importantly, this review highlights the current manufacturing challenges and opportunities for process improvisation and its relevance's for MSCs therapeutics potential.

show abstract

Evaluation of an automated closed fluid management device for processing expanded cytokine‐induced killer cells to use in immunotherapy programs for cancer

Abstract: The automatic wash with the CytoMate showed a good recovery of viable CIK cells during expansion and allowed an efficient manipulation of thawed cells. The use of this simple and efficient washing technique is suitable for clinical-grade processing in cellular therapy protocols.

Cited by 7 publications

References 33 publications

Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial

Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial

Traditional and emerging technologies for washing and volume reducing blood products

Cell Therapy Manufacturing and Quality Control: Current Process and Regulatory Challenges

Contact Info

Product

Resources

About